What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Charles G. Drake mainly focuses on Immunology, Immunotherapy, Immune system, Cancer and Internal medicine.
The study incorporates disciplines such as Cancer research and Prostate cancer in addition to Immunology.
His work deals with themes such as Cytotoxic T cell and Radiation therapy, which intersect with Immunotherapy.
In his study, which falls under the umbrella issue of Cancer, Metastasis is strongly linked to Adverse effect.
His Internal medicine study integrates concerns from other disciplines, such as Surgery and Oncology.
In his study, Avelumab and Tolerability is strongly linked to Colorectal cancer, which falls under the umbrella field of Oncology.
His most cited work include:
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8133 citations)
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (5176 citations)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2048 citations)
What are the main themes of his work throughout his whole career to date?
Charles G. Drake spends much of his time researching Internal medicine, Prostate cancer, Oncology, Immunology and Cancer research.
Enzalutamide, Ipilimumab, Nivolumab, Phases of clinical research and Clinical trial are among the areas of Internal medicine where Charles G. Drake concentrates his study.
The subject of his Prostate cancer research is within the realm of Cancer.
His Melanoma research extends to Cancer, which is thematically connected.
Charles G. Drake usually deals with Oncology and limits it to topics linked to Docetaxel and Placebo.
His Cancer research study combines topics in areas such as Cytotoxic T cell, Blockade, CD8 and Immunotherapy.
He most often published in these fields:
- Internal medicine (43.48%)
- Prostate cancer (43.69%)
- Oncology (39.13%)
What were the highlights of his more recent work (between 2019-2021)?
- Cancer research (32.71%)
- Prostate cancer (43.69%)
- Immunotherapy (32.09%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Prostate cancer, Immunotherapy, Internal medicine and Oncology.
His Cancer research research includes elements of Cytotoxic T cell and T cell, CD8, Immune system.
The concepts of his Prostate cancer study are interwoven with issues in Prostate and Docetaxel.
Immunotherapy is a subfield of Cancer that Charles G. Drake studies.
His biological study spans a wide range of topics, including Inflammation, Transcriptome, Melanoma and Intensive care medicine.
His studies in Oncology integrate themes in fields like Pembrolizumab, Placebo, Clinical endpoint and Antitumor activity.
Between 2019 and 2021, his most popular works were:
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. (116 citations)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented] (88 citations)
- Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens (54 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Oncology, Immunotherapy, Prostate cancer and Cancer research.
In his study, Therapeutic approach and Kidney cancer is inextricably linked to Atezolizumab, which falls within the broad field of Oncology.
His Immunotherapy study is related to the wider topic of Cancer.
His Cancer research includes themes of Inflammation and Intensive care medicine.
His research integrates issues of Progression-free survival, Overall survival and Consensus conference in his study of Prostate cancer.
His research in Cancer research intersects with topics in Cytotoxic T cell, Immune system, Major histocompatibility complex and Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
